Lymphoma: all 5,624 studies
Page 27 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
- A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT04705090Phase 2
- Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in HematologyCompletedNCT04703985
- Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT04702503Phase 1
- EFFECT OF A 16-SESSION QIGONG PROGRAM ON PHYSICAL AND MENTAL HEALTH IN PATIENTS WITH LYMPHOMA: A RANDOMIZED CONTROLLED TRIALCompletedNCT04701554Not applicable
- Lean Body Mass and Side Effects in Patients With LymphomaStatus unknownNCT04698616
- CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.SuspendedNCT04697290Early Phase 1
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160
- Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04696432Phase 1
- The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell LymphomaCompletedNCT04695366
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaWithdrawnNCT04694560
- A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaActive, not recruitingNCT04693676Phase 1
- CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT04690192Phase 1/2
- Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/LymphomaCompletedNCT04689659Phase 2
- the Efficacy and Safety of CLAE in R/R T-ALL/LBLStatus unknownNCT04679506
- Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired ProtocolStatus unknownNCT04677231
- Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT04673617Phase 1/2
- Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.WithdrawnNCT04671420Phase 3
- HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive LymphomaSuspendedNCT04668768Phase 2
- Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
- SARS-CoV-2 Donor-Recipient Immunity TransferCompletedNCT04666025
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04657302Phase 1
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04655677Phase 1
- CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.Status unknownNCT04653649Phase 1/2
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin LymphomaWithdrawnNCT04641806
- CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Active, not recruitingNCT04637763Phase 1
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-ObsCompletedNCT04630275
- FT819 in Subjects With B-cell MalignanciesActive, not recruitingNCT04629729Phase 1
- Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
- Intermittent Fasting and CLL/SLLCompletedNCT04626843Phase 1
- CAR-T Cells in Treating Patients With Relapsed or Refractory NHLStatus unknownNCT04626739Early Phase 1
- A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab EraStatus unknownNCT04624971
- Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLActive, not recruitingNCT04624958Phase 2
- A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab VedotinStatus unknownNCT04624893
- Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 YearsStatus unknownNCT04622579Phase 2
- Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.TerminatedNCT04621604Not applicable
- Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)CompletedNCT04618081
- A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）Status unknownNCT04615468Phase 2
- A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）Status unknownNCT04610970Phase 2
- Study of SNX281 in Subjects With Advanced Solid Tumors and LymphomaTerminatedNCT04609579Phase 1
- Axi-cel in CNS LymphomaActive, not recruitingNCT04608487Phase 1
- CD19-CAR-T2 Cells for CD19 Positive B Cell MalignanciesCompletedNCT04605666Phase 2
- Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaStatus unknownNCT04604028Phase 2
- Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedNCT04602065Phase 1/2
- Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaStatus unknownNCT04600947Phase 2
- Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA StudyCompletedNCT04593277Not applicable
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T CellsCompletedNCT04572308Phase 1
- A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Phase 2
- 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT04566978Early Phase 1
- A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 MalignanciesWithdrawnNCT04556266Phase 1
- Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersTerminatedNCT04553692Phase 1
- Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
- Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT04544059Phase 2
- Supportive Oncology Care At Home RCTActive, not recruitingNCT04544046Not applicable
- Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or LeukemiaActive, not recruitingNCT04541212
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1
- Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNAStatus unknownNCT04539119Phase 3
- POLA+BR for Relapsed or Refractory DLBCLWithdrawnNCT04535102Phase 2
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
- A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma PatientsStatus unknownNCT04516655Phase 2
- Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS LymphomaStatus unknownNCT04514393Phase 2
- Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-CelActive, not recruitingNCT04514029Early Phase 1
- Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell LymphomaStatus unknownNCT04511351Not applicable
- Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
- Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesTerminatedNCT04504708Phase 1/2
- Telemedicine for Early Detection of Cytokine Release Syndrome and NeurotoxicityWithdrawnNCT04503538Not applicable
- Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04502706Phase 1
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- Phase 1 First in Human Study of ZN-d5 as a Single AgentCompletedNCT04500587Phase 1
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
- Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04497688Not applicable
- Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; VitalityCompletedNCT04492553Phase 2
- A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell LymphomaStatus unknownNCT04490590Phase 4
- An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells InjectionStatus unknownNCT04486872Phase 1
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
- Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
- Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
- Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and MelanomaActive, not recruitingNCT04478318Not applicable
- A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of ChinaCompletedNCT04477772Phase 1
- Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
- Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer SurvivorsCompletedNCT04472286
- A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaStatus unknownNCT04470141Phase 2
- A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's LymphomaCompletedNCT04469543
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell TransplantationWithdrawnNCT04464889Phase 1
- A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory LymphomasTerminatedNCT04464798Phase 1
- Interest of a Systematic One-year Monitoring by 18F-FDG PET-CTCompletedNCT04464590
- Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With LymphomaStatus unknownNCT04460508Phase 2
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)Status unknownNCT04457869Phase 2
- The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownNCT04457830Phase 2